Familial Clustering of Staphylococcus aureus Found

This article originally appeared here.
Share this content:
Familial Clustering of <i>Staphylococcus aureus</i> Found
Familial Clustering of Staphylococcus aureus Found

WEDNESDAY, July 6, 2016 (HealthDay News) -- History of Staphylococcus aureus bacteremia in a first-degree relative, especially a sibling, is associated with an increased rate of the disease, according to a study published online July 4 in the Annals of Internal Medicine.

Louise B. Oestergaard, M.D., from Copenhagen University Hospital in Denmark, and colleagues conducted a register-based cohort study to examine whether a history of S. aureus bacteremia in first-degree relatives increases the rate of the disease. They followed 34,774 individuals with a first-degree relative previously hospitalized with S. aureus bacteremia; follow-up was for a median of 7.8 years.

The researchers found that these individuals had a higher rate of S. aureus bacteremia than in the background population (standardized incidence ratio [SIR], 2.49). If the index case patient was a sibling, the estimate was significantly higher than if the index case patient was a parent (SIR, 5.01 versus 1.96). There was no interaction related to the sex of the first-degree relative. The highest rates were seen in individuals exposed to index case patients with non-hospital-acquired infection. Few patients were infected with genetically identical bacteremia isolates.

"A significant familial clustering of S. aureus bacteremia was found, with the greatest relative rate of disease observed in individuals exposed to siblings with a history of the disease," the authors write.

One author disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »